Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

BMC Infectious Diseases

Elamin H Elbasha³  Jean-Pierre Bronowicki⁵  Fred Poordad²  Antoine C El Khoury³  Clifford A Brass¹  Jagpreet Chhatwal⁴  Shannon Allen Ferrante³ 

[1] Novartis, East Hanover, NJ, USA;Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA, USA;Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA;Department of Industrial Engineering, University of Pittsburgh, Pittsburgh, PA, USA;INSERM 954, Centre Hospitalier Universitaire de Nancy, Université de Lorraine, 54500 Vandoeuvre les Nancy, France

关键词: Boceprevir;    Hepatitis c virus;    Economic evaluation;    Cost-effectiveness;   

Others  :  1148749
DOI  :  10.1186/1471-2334-13-190

 received in 2012-05-08, accepted in 2013-03-22,  发布年份 2013

【 摘 要 】

Background

SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with chronic HCV genotype 1. We estimated the long-term impact of triple therapy vs. dual therapy on the clinical burden of HCV and performed a cost-effectiveness evaluation.

Methods

A Markov model was used to estimate the incidence of liver complications, discounted costs (2010 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) of three treatment strategies for treatment-naïve patients with chronic HCV genotype 1. The model simulates the treatment regimens studied in SPRINT-2 in which PR was administered for 4 weeks followed by: 1) placebo plus PR for 44 weeks (PR48); 2) BOC plus PR using response guided therapy (BOC/RGT); and 3) BOC plus PR for 44 weeks (BOC/PR48) and makes projections within and beyond the trial. HCV-related state-transition probabilities, costs, and utilities were obtained from previously published studies. All costs and QALYs were discounted at 3%.

Results

The model projected approximately 38% and 43% relative reductions in the lifetime incidence of liver complications in the BOC/RGT and BOC/PR48 regimens compared with PR48, respectively. Treatment with BOC/RGT is associated with an incremental cost of $10,348 and an increase of 0.62 QALYs compared to treatment with PR48. Treatment with BOC/PR48 is associated with an incremental cost of $35,727 and an increase of 0.65 QALYs compared to treatment with PR48. The ICERs were $16,792/QALY and $55,162/QALY for the boceprevir-based treatment groups compared with PR48, respectively. The ICER for BOC/PR48 compared with BOC/RGT was $807,804.

Conclusion

The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the QALYs in treatment-naive patients with hepatitis C genotype 1. It was also demonstrated that boceprevir-based regimens offer patients the possibility of experiencing great clinical benefit with a shorter duration of therapy. Both boceprevir-based treatment strategies were projected to be cost-effective at a reasonable threshold in the US when compared to treatment with PR48.

【 授权许可】

   
2013 Ferrante et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]World Health Organization (WHO): Hepatitis: facts and figures. 2010. http://www.euro.who.int/en/what-we-do/health-topics/communicable-diseases/hepatitis/facts-and-figures/hepatitis-c webcite (accessed September 9, 2011)
• [2]Amarapurkar D: Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 2000, 15(suppl):E105-E110.
• [3]Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatol 2000, 31:1014-1018.
• [4]Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999–2008. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2009.
• [5]Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14(1):1-21. vii
• [6]Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
• [7]El Khoury AC, Klimack WK, Wallace C, Razavi H: Economic Burden of Hepatitic C Associated Diseases in the United States. J Viral Hepat 2012, 19(3):153-160.
• [8]Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156(4):271-278.
• [9]Razavi H, El Khoury A, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R: Chronic Hepatitis C Virus (Hcv) Disease Burden and Cost in the United States. Hepatol 2012. [Epub ahead of print]
• [10]Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9(4):331-338.
• [11]Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatol 2005, 42:962-973.
• [12]Wilkins T, Malcolm JK, Raina D, Schade RR: Hepatitis C: diagnosis and treatment. Am Fam Physician 2010, 81(11):1351-1357.
• [13]Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatol 2009, 49(4):1335-1374.
• [14]Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa–2.b plus ribavirin compared with interferon alfa–2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
• [15]Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa–2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
• [16]Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group: Peginterferon alfa–2b and ribavirin for the treatment of chronic hepatitis C in blacks and non–Hispanic whites. N Engl J Med 2004, 350:2265-2271. Erratum, N Engl J Med 2004;351:1268
• [17]Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
• [18]Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
• [19]Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2407-2416.
• [20]Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team: Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
• [21]Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatol 2011, 54(4):1433-1444.
• [22]Buti M, Medina M, Casado MA, Wong JB: A cost–effectiveness analysis of peginterferon alfa–2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003, 17(5):687-694.
• [23]Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ: Cost–effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003, 290(2):228-237.
• [24]Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB, German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group: Cost effectiveness of peginterferon –2b plus ribavirin versus interferon –2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003, 52(3):425-432.
• [25]Sullivan SD A, Alberti A, Giuliani G, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J: Cost effectiveness of peginterferon alpha–2a plus ribavirin versus interferon alpha–2b plus ribavirin as initial therapy for treatment–naive chronic hepatitis C. Pharmacoeconomics 2004, 22(4):257-265.
• [26]Younossi Z, Singer ME, McHutchison JG, Shermock KM: Cost effectiveness of interferon 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatol 1999, 30(5):1318-1324.
• [27]Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD: New protease inhibitors for the treatment of chronic hepatitis C a cost-effectiveness analysis. Ann Intern Med 2012, 156:279-290.
• [28]Cardoso AC, Moucar R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010, 52(5):652-657.
• [29]Thein HH, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatol 2008, 48(2):418-431.
• [30]Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G: Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterol 1997, 112(2):463-472.
• [31]Gentilini P, Laffi G, La Villa G, Romanelli RG, Buzzelli G, Casini-Raggi V, Melani L, Mazzanti R, Riccardi D, Pinzani M, Zignego AL: Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997, 92(1):66-72.
• [32]Serfaty L, Chazouillères O, Bonnand AM, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatol 1998, 27(5):1435-1440.
• [33]Benvegnu L, Gios M, Boccato S, Alberti A: Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004, 53:744-749.
• [34]Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M: The natural history of compensated cirrhosis due to hepatitis c virus: a 17-year cohort study of 214 patients. Viral Hepat 2006, 43(6):1303-1310.
• [35]Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328(25):1797-1801.
• [36]Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU: Hepatitis c virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatol 1997, 25(3):754-758.
• [37]Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis c in japan: Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999, 131(3):174-181.
• [38]Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Yano K, Komori A, Migita K, Nakamura M, Nagahama H, Sasaki Y, Miyakawa Y, Ishibashi H: Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis c virus. J Gastroenterol 2011, 46(1):92-100.
• [39]Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Solà R: Natural history of decompensated hepatitis c virus-related cirrhosis: A study of 200 patients. J Hepatol 2004, 40(5):823-830.
• [40]UNOS and the Division of Organ Transplantation, Health Resources and Service Administration: Center Specific Report: liver data, UNOS Update 1995. 1994, 11. 15–18
• [41]Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ: Liver Transplantation in the united states, 1999–2008. Am J Transpl 2010, 10(4):89-99.
• [42]Davis GL, Alter MJ, El–Serag H, Poynard T, Jennings LW: Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterol 2010, 138(2):513-521.
• [43]Lang K, Danchenko N, Gondek K, Shah S, Thompson D: The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009, 50(1):89-99.
• [44]Arias E: United states life tables, 2006: National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 2010, 58:1.
• [45]Wolfe RA, Merion RM, Roys EC, Port FK: Trends in Organ Donation and Transplantation in the United States, 1999–2008. Am J Transplant 2010, 10(4p2):961-972.
• [46]First DataBank, Inc: Drug databases. [http://www.firstdatabank.com/Support/drug-pricing-policy.aspz webcite]
• [47]Wilson J, Yao G, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C: A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007, 11(13):1-202. iii–iv
• [48]Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG: Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006, 26:391-400.
• [49]McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI: All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care 2011, 17:531-546.
• [50]Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V: Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011, 45:e17-24.
• [51]Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M: Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003, 98:630-638.
• [52]Tong M, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion–associated hepatitis C. N Engl J Med 1995, 332(22):1463-1466.
• [53]Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999, 340(16):1228-1233.
• [54]Bennet WG, Inoue Y, Beck R, Wong JB, Pauker SG, Davis GL: Estimates of the Cost-Effectiveness of a Single Course of Interferon-a2b in Patients with Histologically Mild Chronic Hepatitis C. Ann Intern Med 1997, 127(10):855-865.
• [55]Gines P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C: Compensated cirrhosis – natural-history and prognostic factors. Hepatol 1987, 7(1):122-128.
• [56]Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55(9):1350-1359.
• [57]Victrelis prescribing information. [http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf webcite] Accessed March 21, 2012
• [58]van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308(24):2584-2593.
• [59]Owens DK: Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998, 13(10):716-717.
• [60]Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP: Long-term mortality after transfusion-associated non-a, non-B hepatitis: The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992, 327:1906-1911.
• [61]Su J, Brook RA, Kleinman NL, Corey-Lisle P: The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatol 2010, 52(2):436-442.
• [62]DiBonaventura M, Wagner JS, Yuan Y, L’Italien G, Langley P, Ray Kim W: The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011, 14(2):253-261.
• [63]El Khoury AC, Vietri J, Prajapati G: The burden of untreated hepatitis C virus infection: a US patients’ perspective. Dig Dis Sci 2012, 57(11):2995-3003.